Company Filing History:
Years Active: 1999-2003
Title: Guido Franceschini: Innovator in Apolipoprotein Research
Introduction
Guido Franceschini is a notable inventor based in Milan, Italy. He has made significant contributions to the field of biochemistry, particularly in the study of apolipoproteins. With a total of 2 patents, his work has implications for treating cardiovascular diseases.
Latest Patents
Franceschini's latest patents include the "Dimer of molecular variant of apolipoprotein and processes for the production thereof." This patent describes the isolation and characterization of substantially pure dimers of Apolipoprotein AI-Milano (APO-AI-M/APO AI-M) from plasma. The dimer can also be produced in a recombinant system. Pharmaceutical compositions comprising the ApoAI-AI-M/ApoAI-M are detailed, indicating potential treatments for patients with atherosclerosis or cardiovascular diseases. Additionally, the dimer can be utilized to prevent thrombosis in various clinical situations, both at the arterial and venous levels. It can also function as a prodrug for the monomer.
Career Highlights
Throughout his career, Franceschini has worked with prominent companies in the pharmaceutical industry. Notable among these are Esperion Therapeutics, Inc. and Pharmacia & Upjohn Aktiebolag. His work in these organizations has contributed to advancements in medical treatments and drug development.
Collaborations
Franceschini has collaborated with esteemed colleagues in his field, including Cesare Sirtori and Erik Holmgren. These partnerships have fostered innovation and research in the area of apolipoproteins.
Conclusion
Guido Franceschini's contributions to the field of biochemistry, particularly through his patents and collaborations, highlight his role as an innovator in medical research. His work continues to have a significant impact on the treatment of cardiovascular diseases.